Rivaroxaban: can we trust the evidence?

BMJ. 2016 Feb 3;352:i575. doi: 10.1136/bmj.i575.
No abstract available

MeSH terms

  • Anticoagulants / therapeutic use
  • Atrial Fibrillation / complications
  • Brain Ischemia / prevention & control*
  • Drug Approval
  • Embolism / prevention & control
  • Europe
  • Evidence-Based Medicine / standards*
  • Factor Xa Inhibitors / therapeutic use*
  • Humans
  • International Normalized Ratio / instrumentation
  • International Normalized Ratio / standards
  • Rivaroxaban / therapeutic use*
  • Stroke / prevention & control*
  • United States
  • United States Food and Drug Administration
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Warfarin
  • Rivaroxaban